相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records
Candice Wang et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2020)
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study
Mette Deleuran et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment
Yoav Nahum et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2020)
Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus
Jonathan Silverberg et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension
M. J. Cork et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial
Emma Guttman-Yassky et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis A Phase 3 Randomized Clinical Trial
Eric L. Simpson et al.
JAMA DERMATOLOGY (2020)
Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial
Amy S. Paller et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2020)
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phaseIIItrials
E. L. Simpson et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Conjunctivitis in patients with atopic dermatitis treated with dupilumab is associated with higher baseline serum levels of immunoglobulin E and thymus and activation-regulated chemokine but not clinical severity in a real-world setting
Hideaki Uchida et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Revisiting Therapies for Atopic Dermatitis that Failed Clinical Trials
Gaurav Agnihotri et al.
CLINICAL DRUG INVESTIGATION (2020)
Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis A Phase 2b Randomized Clinical Trial
Emma Guttman-Yassky et al.
JAMA DERMATOLOGY (2020)
Profile of Baricitinib and Its Potential in the Treatment of Moderate to Severe Atopic Dermatitis: A Short Review on the Emerging Clinical Evidence
Maddalena Napolitano et al.
JOURNAL OF ASTHMA AND ALLERGY (2020)
Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb
Andreas Wollenberg et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
Emma Guttman-Yassky et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Dupilumab: short-term effectiveness and security in real clinical practice - A retrospective multicentric study
R. Ruiz-Villaverde et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2019)
GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis
Emma Guttman-Yassky et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Real-world effectiveness and safety of dupilumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective study
H. Uchida et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials
J. Silverberg et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Conjunctivitis in dupilumab clinical trials
B. Akinlade et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial
Roy Fleischmann et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial
Robert Bissonnette et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
The IL-13-OVOL1-FLG axis in atopic dermatitis
Kazuhisa Furue et al.
IMMUNOLOGY (2019)
Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis A Phase 2 Randomized Clinical Trial
Melinda J. Gooderham et al.
JAMA DERMATOLOGY (2019)
Atopic dermatitis endotypes and implications for targeted therapeutics
Tali Czarnowicki et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Atopic Dermatitis Is an IL-13-Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis
Lam C. Tsoi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment
Emma Guttman-Yassky et al.
EXPERIMENTAL DERMATOLOGY (2018)
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE)
M. de Bruin-Weller et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteers
Paul Baverel et al.
DRUG METABOLISM AND PHARMACOKINETICS (2018)
Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study
Kenji Kabashima et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)
Eric L. Simpson et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Alopecia Areata in Severe Atopic Dermatitis Treated With Dupilumab
Manuel Jorge Rial Prado
JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY (2018)
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Daniella M. Schwartz et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Thomas Ruzicka et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Atopic dermatitis and psoriasis: two different immune diseases or one spectrum?
Emma Guttman-Yassky et al.
CURRENT OPINION IN IMMUNOLOGY (2017)
Atopic dermatitis phenotypes and the need for personalized medicine
Beatriz Cabanillas et al.
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY (2017)
The Role of Interleukins 4 and/or 13 in the Pathophysiology and Treatment of Atopic Dermatitis
Jonathan I. Silverberg et al.
DERMATOLOGIC CLINICS (2017)
The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study
O. Nemoto et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
E. L. Simpson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications
Mayte Suarez-Farinas et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
Association of Vitiligo and Alopecia Areata With Atopic Dermatitis A Systematic Review and Meta-analysis
Girish C. Mohan et al.
JAMA DERMATOLOGY (2015)
Suppression of Cytokine Signaling by SOCS3: Characterization of the Mode of Inhibition and the Basis of Its Specificity
Jeffrey J. Babon et al.
IMMUNITY (2012)
分享论文
